RD-23
RD-23 is an orally active and selective RET PROTAC degrader. RD-23 promotes ubiquitination and degradation of RETG810C mutation, with a DC50 value of 11.7 nM. RD-23 inhibits the activation of downstream Shc signaling and induces Apoptosis. RD-23 can be used for the research of RET-related cancers (Pink: RET ligand-2 ; Blue: E3 ligase CRBN ligand; Black: linker).
Product Specifications
CAS Number
3053537-06-4
UNSPSC
12352005
Target
Apoptosis; PROTACs; RET
Related Pathways
Apoptosis; PROTAC; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
N#CC1=C2C(C3=CC=C(N=C3)N4CC5CC(C4)N5CC6=CC=C(N=C6)OC)=CC(N7CCC(CC7)N8CCN(CC8)CCCC#CC9=CC=CC%10=C9CN(C%10=O)C(C(N%11)=O)CCC%11=O)=CN2N=C1
Molecular Formula
C52H56N12O4
Molecular Weight
913.08
References & Citations
[1]Hualong M, et al. Discovery of a Selective and Orally Bioavailable RET Degrader with Effectiveness in Various Mutations. J Med Chem. 2025 Jan 7.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Histone H1 (AE-4), CF640R conjugate, 0.1mg/mL
Cytokeratin, LMW (AE-1), CF740 conjugate, 0.1mg/mL
CD50 (ICAM-3) (186-2G9), CF488A conjugate, 0.1mg/mL
Pmel17 / gp100 / SILV (NKI-beteb), CF647 conjugate, 0.1mg/mL
